Cullinan Oncology Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
CGEM Nasdaq 8731 https://www.cullinanoncology.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Cullinan Oncology Inc

Cullinan Oncology Provides Corporate Update and Reports Third Quarter 2023 Financial Results - Nov 8th, 2023 12:00 pm
Cullinan Oncology to Present Data Demonstrating Progress Across Its Broad Immunotherapy-Pipeline at SITC 2023 - Nov 3rd, 2023 4:01 pm
Cullinan Oncology to Participate in Upcoming Investor Conferences - Oct 30th, 2023 12:00 pm
Cullinan Oncology Provides Corporate Update and Reports Second Quarter 2023 Financial Results - Aug 10th, 2023 11:00 am
Cullinan Oncology Announces First Patient Dosed in Phase 1 Trial Evaluating CLN-978, a Novel CD19xCD3 T cell Engager, in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma - Aug 9th, 2023 11:00 am
REZILIENT3 Global First-Line Trial of Zipalertinib Launched in Patients With Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations - Aug 3rd, 2023 8:15 pm
Why Shares of Cullinan Oncology Jumped This Week - Jun 9th, 2023 8:07 pm
Cullinan Oncology to Present First Monotherapy Clinical Data for CLN-619, a Novel Anti-MICA/B Antibody, at ASCO 2023 - May 25th, 2023 9:00 pm
Cullinan Oncology Provides Corporate Update and Reports First Quarter 2023 Financial Results - May 11th, 2023 8:01 pm
Cullinan Oncology to Present First Clinical Data Evaluating Novel Anti-MICA/B Antibody, CLN-619, in Patients with Advanced Solid Tumors at ASCO 2023 - Apr 26th, 2023 2:08 pm
Cullinan Oncology to Participate in Stifel’s 2023 Targeted Oncology Days - Apr 20th, 2023 11:00 am
12 Cheap Healthcare Stocks to Buy in 2023 - Mar 29th, 2023 2:13 pm
Cullinan Oncology Announces U.S. FDA Clearance of Investigational New Drug Application for CLN-617, a Novel Fusion Protein Harnessing IL-2 and IL-12 Cytokines - Mar 27th, 2023 11:00 am
Cullinan Oncology to Present New Preclinical Data for CLN-619 and CLN-617 at the 2023 American Association for Cancer Research Annual Meeting - Mar 14th, 2023 8:35 pm
Cullinan Oncology Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results - Mar 9th, 2023 12:00 pm
Cullinan Oncology to Participate in Cowen’s 43rd Annual Health Care Conference - Feb 27th, 2023 1:00 pm
Cullinan Oncology Licenses U.S. Rights to the First Clinical-Stage B7H4 x 4-1BB Bispecific Immune Activator from Harbour BioMed - Feb 14th, 2023 12:00 am
Cullinan Oncology to Participate in the Guggenheim 5th Annual Oncology Conference and the SVB Securities Global Biopharma Conference - Feb 2nd, 2023 9:01 pm
Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Feb 1st, 2023 9:42 pm
Cullinan Oncology Announces U.S. FDA Clearance of Investigational New Drug Application for CLN-978, a Novel T-Cell Engager for the Treatment of Relapsed/Refractory B-cell Non-Hodgkin Lymphoma - Jan 24th, 2023 1:00 pm